Skip to main content

Summary

for people ages 13 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Official Title

A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis

Keywords

Pruritus Atopic Dermatitis Dermatitis Dermatitis, Atopic Eczema Serlopitant

Eligibility

You can join if…

Open to people ages 13 years and up

  • Male or female, age 13 years or older
  • Pruritus prior to and during the initial screening period
  • Diagnosis of atopic dermatitis
  • Judged to be in good health in the investigator's opinion

You CAN'T join if...

  • Prior treatment with study drug or similar drug
  • Pruritus due to another reason besides atopic dermatitis
  • Presence of any medical condition or disability that could interfere with study
  • History of hypersensitivity to serlopitant or any of its components
  • Currently pregnant or male partner of pregnant female
  • Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding

Locations

  • Study Site 333 accepting new patients
    San Francisco, California, United States
  • Study Site 376 accepting new patients
    Santa Monica, California, United States
  • Study Site 338 accepting new patients
    Los Angeles, California, United States
  • Study Site 334 accepting new patients
    Cerritos, California, United States
  • Study Site 366 accepting new patients
    Fountain Valley, California, United States
  • Study Site 383 accepting new patients
    Toluca, California, United States
  • Study Site 387 accepting new patients
    Las Vegas, Nevada, United States
  • Study Site 374 accepting new patients
    Oceanside, California, United States
  • Study Site 386 accepting new patients
    Encinitas, California, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Menlo Therapeutics Inc.
ID
NCT02975206
Phase
Phase 2
Lead Scientist
Sarah Arron
Study Type
Interventional
Last Updated
November 6, 2017
I’m interested in this study!